A focused liquid biopsy assay for research
Benefits of the PGDx focused liquid biopsy assay
PGDx elio plasma resolve is a pan solid tumor NGS liquid biopsy assay that identifies key genomic alterations and guideline-supported biomarkers with high accuracy and sensitivity. It features proprietary methods for detecting microsatellite instability (MSI), as well as complex structural alterations and amplifications.
Thoroughly validated
Robustly tested in clinical trials to ensure highly accurate results
Liquid biopsy format
Access targeted insights without the need for an invasive tissue biopsy
Available globally
Our kitted solutions are available now for researchers across the globe
Distributed
Full coding genes for sequence mutations
Days* sample-to result turnaround time
Sequencing coverage
SNVs, indels, amplifications and translocations
* Kitted workflow. Not inclusive of DNA extraction and annotated reporting
PGDx elio™ bioinformatics rapidly and accurately identifies cancer mutations, empowering every lab to provide timely and trustworthy results. High quality training data, expert curation and machine learning algorithms combine to provide best-in-class identification of cancer mutations.
PGDx elio plasma resolve evaluates a targeted panel of 33 well-characterized cancer genes. Analyses for sequence mutations or rearrangements can be performed together or separately, depending on the specific alterations of interest. Get the technical specifications:
Patent Disclaimer
For Research Use Only.
Personal Genome Diagnostics Inc. (PGDx) is a subsidiary of Laboratory Corporation of America Holdings, using the brand Labcorp.
©2023 Laboratory Corporation of America® Holdings. All rights reserved.